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A B S T R A C T
Background
Survivors of stroke due to intracerebral haemorrhage (ICH) are at risk of thromboembolism. Antithrombotic (antiplatelet or anticoag-
ulant) treatments may lower the risk of thromboembolism after ICH, but they may increase the risks of bleeding.
Objectives
To determine the overall effectiveness and safety of antithrombotic drugs for people with ICH.
Search methods
We searched theCochrane Stroke GroupTrials Register (24March 2017). We also searched theCochrane Central Register of Controlled
Trials (CENTRAL: the Cochrane Library 2017, Issue 3), MEDLINE Ovid (from 1948 to March 2017), Embase Ovid (from 1980 to
March 2017), and online registries of clinical trials (8 March 2017). We also screened the reference lists of included trials for additional,
potentially relevant studies.
Selection criteria
We selected all randomised controlled trials (RCTs) of any antithrombotic treatment after ICH.
Data collection and analysis
Three review authors independently extracted data. We converted categorical estimates of effect to the risk ratio (RR) or odds ratio
(OR), as appropriate. We divided our analyses into short- and long-term treatment, and used fixed-effect modelling for meta-analyses.
Three review authors independently assessed the included RCTs for risks of bias and we created a ’Summary of findings’ table using
GRADE.
1Antithrombotic treatment after stroke due to intracerebral haemorrhage (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Main results
We included two RCTs with a total of 121 participants. Both RCTs were of short-term parenteral anticoagulation early after ICH:
one tested heparin and the other enoxaparin. The risk of bias in the included RCTs was generally unclear or low, with the exception
of blinding of participants and personnel, which was not done. The included RCTs did not report our chosen primary outcome (a
composite outcome of all serious vascular events including ischaemic stroke, myocardial infarction, other major ischaemic event, ICH,
major extracerebral haemorrhage, and vascular death). Parenteral anticoagulation did not cause a statistically significant difference in
case fatality (RR 1.25, 95% confidence interval (CI) 0.38 to 4.07 in one RCT involving 46 participants, low-quality evidence), ICH,
or major extracerebral haemorrhage (no detected events in one RCT involving 75 participants, low-quality evidence), growth of ICH
(RR 1.64, 95% CI 0.51 to 5.29 in two RCTs involving 121 participants, low-quality evidence), deep vein thrombosis (RR 0.99, 95%
CI 0.49 to 1.96 in two RCTs involving 121 participants, low quality evidence), or major ischaemic events (RR 0.54, 95% CI 0.23 to
1.28 in two RCTs involving 121 participants, low quality evidence).
Authors’ conclusions
There is insufficient evidence from RCTs to support or discourage the use of antithrombotic treatment after ICH. RCTs comparing
starting versus avoiding antiplatelet or anticoagulant drugs after ICH appear justified and are needed in clinical practice.
P L A I N L A N G U A G E S U M M A R Y
Drugs to prevent clots after bleeding in the brain
Review question
What is the effectiveness and safety of medications used to prevent clots (antithrombotic treatments) both in the early stages and long-
term in people who have had a bleed within their brain (intracerebral haemorrhage)?
Background
People with stroke due to bleeding in the brain (also known as intracerebral haemorrhage: ICH) are more likely to develop clots in
their blood vessels due to immobility (in the early stages) and due to other medical conditions (in the long term). Blood clots in the
lungs, brain, or other organs can cause serious illness or death. Drugs that prevent clots (also known as ’antithrombotic drugs’) might
be useful to stop clot formation in people with ICH. However, these drugs can also cause serious bleeding complications.
Study characteristics
From extensive searches conducted on 8 March 2017, we identified two relevant randomised controlled trials (RCTs), which are the
fairest tests of treatment. There were 121 participants in these two trials, which compared blood-thinning ’anticoagulant’ drugs (heparin
in one and enoxaparin in the other) delivered by injections under the skin versus no anticoagulant drug soon after ICH.
Key results
The primary outcome of this review was the combined risk of several important clinical outcome events (such as another intracerebral
haemorrhage, ischaemic stroke, or death from a cardiovascular cause). We were not able to calculate this outcome for the included
studies. Neither RCT reported on recovery of independence or mental abilities. One RCT involving 46 participants reported on case
fatality associated with short-term antithrombotic treatment, and did not find a statistically meaningful effect. For the consequences
of treatment that could be analysed, the risk estimates were imprecise and uncertain. Therefore, the potential benefits and harms of
antithrombotic drugs soon after a stroke due to bleeding in the brain remain unclear. New high-quality RCTs investigating the use of
antithrombotic treatment after stroke due to ICH appear justified and are needed.
Quality of the evidence
The overall quality of the evidence was low. This is due to the way the included trials were conducted and reported, as well as the small
number of participants, which may not have been high enough to detect small differences between the antithrombotic treatment and
no antithrombotic treatment groups.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Short- term antithrombotic treatment
Patient or population: people with intracerebral haemorrhage
Setting: any
Intervention: ant ithrombotic treatment (parenteral ant icoagulat ion)
Comparison: no ant ithrombotic treatment
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with no antithrom-
botic treatment
Risk with Antithrom-
botic treatment
Composite vascular
endpoint
Study populat ion not est imable (0 studies) - We were unable to
calculate the compos-
ite endpoint because
no included study re-
ported all component
endpoints
Death Study populat ion RR 1.25
(0.38 to 4.07)
46
(1 RCT)
⊕⊕©©
LOW 12
-
174 per 1,000 217 per 1,000
(66 to 708)
Growth of ICH Study populat ion RR 1.64
(0.51 to 5.29)
121
(2 RCTs)
⊕⊕©©
LOW 12
-
51 per 1,000 83 per 1,000
(26 to 269)
ICH Study populat ion not est imable 75
(1 RCT)
⊕⊕©©
LOW 12
-
0 per 1,000 0 per 1,000
(0 to 0)
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Major extracerebral
haemorrhage
Study populat ion not est imable 75
(1 RCT)
⊕⊕©©
LOW 12
-
0 per 1,000 0 per 1,000
(0 to 0)
Deep vein thrombosis Study populat ion RR 0.99
(0.46 to 1.96)
121
(2 RCTs)
⊕⊕©©
LOW 12
-
186 per 1,000 185 per 1,000
(86 to 365)
Other major ischaemic
events
Study populat ion RR 0.54
(0.23 to 1.28)
121
(2 RCTs)
⊕⊕©©
LOW 12
-
186 per 1,000 101 per 1,000
(43 to 239)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1This included RCT/ s has serious risk of bias due to it not describing random sequence generat ion or allocat ion concealment,
as well as lack of blinding.
2The optimal information size (OIS) criterion is not met. The sample size of this study is probably lower than the minimum
number of part icipants required for a trial adequately powered to ident if y a stat ist ically signif icant dif f erence for this outcome.
4
A
n
tith
ro
m
b
o
tic
tre
a
tm
e
n
t
a
fte
r
stro
k
e
d
u
e
to
in
tra
c
e
re
b
ra
l
h
a
e
m
o
rrh
a
g
e
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
B A C K G R O U N D
Description of the condition
Stroke due to spontaneous (non-traumatic) intracerebral haem-
orrhage (ICH) is caused by the extravasation of blood into brain
parenchyma following rupture of a cerebral artery or arteriole.
The Global Burden of Disease (GBD) Study estimated that in the
world in 2010 there were 5.32million incident (first ever) haemor-
rhagic strokes (i.e. ICHand subarachnoid haemorrhage), resulting
in an incidence of 82 (95% confidence interval (CI) 72 to 93) per
100,000 person-years (Krishnamurthi 2010). Hypertension is the
strongest risk factor for ICH, with a population attributable risk of
approximately 50% (O’Donnell 2016). Over recent decades, the
prevalence of the use of antithrombotic (antiplatelet or anticoag-
ulant) drug use at the time of ICH has increased to approximately
50% (Béjot 2013; Lovelock 2007). Population-based case-control
studies report that, among people with ICH, about 20% were
taking anticoagulants and 30% were taking antiplatelet agents at
the onset of symptoms, whereas among populations free of ICH,
about 6% were taking anticoagulants and about 23% were taking
antiplatelet agents (Lauer 2013).
Survivors of ICH are at risk of recurrent ICH, particularly if the
underlying cause of the incident ICH is not treated (e.g. hyper-
tension, arteriovenous malformation). They are also at risk of is-
chaemic stroke, ischaemic heart disease, atrial fibrillation, and sys-
temic embolism.
A review of observational studies found that the annual risk of
recurrent ICH was between 1.8% and 7.4% (Poon 2014). Three
studies compared outcomes after ICH in different locationswithin
the brain, two of which found that the risk of recurrence after lobar
ICH appeared higher than after deep ICH (Poon 2014). Most pa-
tients in the world have ICH diagnosis and location confirmed by
computed tomography (CT). However, some patients have mag-
netic resonance imaging (MRI), on which brain microbleeds are
biomarkers of a higher risk of both recurrent ischaemic stroke and
ICH (Cordonnier 2007; Wilson 2016). In studies that quantified
the risks of both recurrent ICH and ischaemic stroke after ICH,
these risks appeared similar (Poon 2014).
Description of the intervention
Antithrombotic (anticoagulant and antiplatelet) drugs are effec-
tive for preventing thrombosis and embolism of clots in the brain,
heart, limbs, and lungs.However, their effects are unknown inpeo-
plewho also have a past history of ICH, because theywere excluded
from the RCTs that demonstrated the benefits of antithrombotic
drugs. There is uncertainty about whether to start these drugs after
ICH (Al-Shahi Salman 2014; Falcone 2014;Molina 2011; Steiner
2011).
Consequently, there is variation in clinical practice: the proportion
of patients starting antithrombotic drugs after ICH varies from
11% to 45% in different countries (Pasquini 2014).
The indications for restarting antithrombotic drugs after ICHmay
include the presence of prevalent risk factors for thromboembolism
(e.g. atrial fibrillation, valvular heart disease, and atherosclerosis).
The indications for starting antithrombotic drugs for the first time
after ICHmay include new risk factors for thromboembolism (e.g.
immobility, or new atrial fibrillation) or vaso-occlusive events (e.g.
deep vein thrombosis and pulmonary embolism). Antithrombotic
drugs after ICH can be given for prophylaxis over the short term
(e.g. immobility during the period of hospitalisation following
ICH) with low doses of low-molecular-weight heparin or unfrac-
tionated heparin, or over the long term (e.g. atrial fibrillation, pre-
vious vaso-occlusive disease) with oral antiplatelet or full-dose oral
anticoagulant drugs.
Why it is important to do this review
A previous systematic review identified three RCTs that included
a subset of people who received antithrombotic treatment after
ICH, but it did not identify any clear benefits or harms of doing
so (Keir 2002).
Some observational studies have addressed the use of antithrom-
botic drugs after ICH, but did not identify associations with ben-
eficial or adverse outcomes that were large enough to preclude
the need for RCTs (Chao 2016; Chong 2012; Claassen 2008; De
Vleeschouwer 2005; Flynn 2010a; Hawryluk 2010; Kuramatsu
2015; Nielsen 2015; Pennlert 2016; Poli 2014; Viswanathan
2006).
Whether and when to use antithrombotic drugs after ICH was
identified as a dilemma in the European Stroke Organisation’s
recent ICH guideline (Steiner 2014), which was unable to make
any strong recommendations about the use of these drugs.
O B J E C T I V E S
Primary objective
To determine the overall effectiveness and safety of antithrombotic
drugs for people with ICH.
Secondary objective
To determine whether the effectiveness and safety of antithrom-
botic treatment differs in prespecified subgroups (see Subgroup
analysis and investigation of heterogeneity).
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M E T H O D S
Criteria for considering studies for this review
Types of studies
We sought all RCTs that made comparisons of starting versus
avoiding antithrombotic drugs, or direct comparisons of different
classes of antithrombotic drugs, for preventing thromboembolism
after ICH. We included RCTs published in any language and
planned to arrange translation where the language of publication
was not English.
Types of participants
We sought RCTs whose participants survived a spontaneous ICH
that had been diagnosed by CT or MRI. We included RCTs
whether or not they had taken antithrombotic drugs at the time
of ICH.
Types of interventions
We sought RCTs that compared the use of any antithrombotic
drug against no antithrombotic treatment, as well as RCTs that
compared different antithrombotic drugs. We placed no con-
straints on dosage, route of administration, or duration of admin-
istration. We separated RCTs investigating short-term treatment
(for example, with low-molecular-weight heparin or unfraction-
ated heparin in the acute post-stroke phase) and those investigat-
ing long-term treatment (for example, with oral anticoagulants or
antiplatelets).
We excluded RCTs in which the effects of antithrombotic drugs
might have been confounded by the administration of another
active drug to participants (e.g. if allocation to this additional
treatment was not evenly distributed between groups in an RCT,
or was not randomly allocated).
Types of outcome measures
Primary outcomes
• Composite outcome of ’all serious vascular events’
(ischaemic stroke, myocardial infarction, other major ischaemic
event, ICH, major extracerebral haemorrhage, and vascular
death) during the scheduled follow-up period.
Secondary outcomes
• Death during the scheduled follow-up period.
• The individual components of the composite vascular
outcome: ischaemic stroke, myocardial infarction, other major
ischaemic event, ICH, major extracerebral haemorrhage, and
vascular death.
• Growth of ICH.
• Deep vein thrombosis.
• Functional status (where measured using validated scales) at
the end of the scheduled follow-up period.
• Cognitive status (where measured using validated scales) at
the end of the scheduled follow-up period.
Search methods for identification of studies
See the ’Specialized register’ section in the Cochrane Stroke Group
module. We searched for RCTs in any language and planned to
arrange for the translation of relevant articles where necessary.
Electronic searches
We searched the Cochrane Stroke Group trials register in March
2017 and the following electronic databases, using search strategies
that the Cochrane Stroke Group’s Information Specialist helped
us design:
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 3) in the Cochrane Library (searched 8
March 2017) (Appendix 1);
• MEDLINE Ovid (1946 to 8 March 2017) (Appendix 2);
• Embase Ovid (1974 to 8 March 2017) (Appendix 3).
We also searched the following trials registers:
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (clinicaltrials.gov; searched 2 March 2017)
(Appendix 4);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (apps.who.int/trialsearch;
searched 2 March 2017) (Appendix 4);
• ISRCTN Registry (www.isrctn.com; searched 2 March
2017) (Appendix 4);
• Stroke Trials Registry - the Internet Stroke Center (
www.strokecenter.org/trials/; searched 2 March 2017) (Appendix
4).
Searching other resources
We screened the reference lists of relevant studies to identify fur-
ther studies for potential inclusion in the review. We also used the
Science Citation Index Cited Reference Search for forward track-
ing of relevant articles.
Data collection and analysis
Selection of studies
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Three review authors (LAP, JB, EF) independently screened the
titles and abstracts of the references obtained as a result of our
searching activities, and excluded reports that were obviously irrel-
evant. We retrieved full-text articles for the remaining references,
and the same three review authors independently screened these
full-text articles to identify studies for inclusion, and identified
and recorded reasons for the exclusion of ineligible studies. We
resolved any disagreements through discussion or, if required, we
planned on consulting a fourth review author (EB). We collated
multiple reports of the same study so that each study, not each ref-
erence, is the unit of interest in the review. We recorded the selec-
tion process and completed a PRISMA flow diagram (See Figure
1 in the Results of the search section).
Data extraction and management
Three review authors (LAP, JB, EF) independently extracted data
from included studies using a preformulated data collection form.
Assessment of risk of bias in included studies
Three review authors (LAP, JB, EF) independently assessed risks
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved any disagreements by discussion or by involving an-
other review author (EB). We assessed the risks of bias according
to the following domains.
• Random sequence generation
• Allocation concealment
• Blinding of participants and personnel
• Blinding of outcome assessment
• Incomplete outcome data
• Selective outcome reporting
• Other potential bias
We graded the risk of bias for each domain as high, low or unclear
and provide information from the study report, together with a
justification for our judgement, in the ’Risk of bias’ tables.
Measures of treatment effect
We intended to:
• convert categorical estimates of effect to the risk ratio (RR)
or odds ratio (OR), if required;
• express measures of survival as a hazard ratio (HR); and
• use summary measures obtained from univariate or, where
RCTs used the same covariates for adjustment, multivariable
analyses.
Unit of analysis issues
Repeated observations on participants
We planned to analyse functional and cognitive status at end of
follow-up, and not to use repeat observations during follow-up. If
one RCT (or only a fewRCTs) had amuch longer period of follow-
up than the majority of RCTs (for example, two years compared
with six months in the majority of trials) we intended to perform
a sensitivity analysis using the six-month observations from all
RCTs.
Events that may recur
We analysed the first event in all participants, and not later events.
Multiple intervention groups
Where a RCT contained multiple treatment groups that were all
compared with just one control group, we intended to ensure
that the placebo group was shared between the multiple treatment
groups by dividing it into the appropriate number of subgroups
and conducting separate, independent comparisons.
Dealing with missing data
We contacted RCT authors for unpublished data if relevant data
were missing. If only a minority (less than half ) of data were miss-
ing, we planned to ignore the missing data and perform a ’com-
plete set analysis’. If more substantial amounts of data were miss-
ing, and there was a chance that data were not missing at random,
we planned to perform sensitivity analyses assuming both a best-
case and a worst-case scenario, or apply statistical imputation or
models, or both, to account for the missing data. A best-case sce-
nario meant that we assumed that all missing data in the inter-
vention group represent good outcomes and all missing data in
the control group represent poor outcomes. A worst-case scenario
meant that we assumed that all missing data in the intervention
group represent poor outcomes and all missing data in the control
group represent good outcomes.
Assessment of heterogeneity
We investigated inconsistency between included RCTs using the
I2 statistic. We interpreted this value using the guide provided in
Chapter 9.5.2 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011):
• 0% to 40%: might not be important
• 30% to 60%: may represent moderate heterogeneity
• 50% to 90%: may represent substantial heterogeneity
• 75% to 100%: represents considerable heterogeneity
If we observed substantial inconsistency in our data, we intended
to use sensitivity analysis to elucidate which factors might explain
the inconsistency.
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Assessment of reporting biases
We included all published and unpublished data and secondary
publications from RCTs. If we included a sufficient number of
RCTs (more than 10), we planned to assess the likelihood of re-
porting biases through the use of a funnel plot.
Data synthesis
If RCTs were sufficiently similar, we planned to conduct a meta-
analysis by pooling the appropriate data using Review Manager
5 (RevMan 2014). We planned to calculate the risk ratio (RR),
odds ratio (OR), or hazard ratio (HR) for each outcome from data
extracted from included RCTs using the Peto fixed-effect method,
or a random-effects model if there was significant heterogeneity
between RCTs. We defined significant heterogeneity as substantial
clinical or methodological diversity between RCTs such that the
true effect measure is no longer uniform.
’Summary of findings’ table
We created a ‘Summary of findings’ table using the GRADEpro
Guideline Development Tool (GRADEpro GDT), and included
the following outcomes for short-term antithrombotic treatment:
the composite outcome of all serious vascular events, death, growth
of ICH, ICH, major extracerebral haemorrhage, deep vein throm-
bosis, other major ischaemic events, functional status, and cogni-
tive status. We planned a ’Summary of findings’ table for long-
term antithrombotic treatment which included the following out-
comes: the composite outcome of all serious vascular events, death,
functional status, and cognitive status. Two review authors (LAP,
JB) independently classified the quality of the evidence as being
’high’, ’moderate’, ’low’, or ’very low’, based on the presence and
extent of the following five criteria outlined in theCochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011):
• Limitations in the design and implementation of the
contributing trials
• Indirectness of evidence
• Unexplained heterogeneity or inconsistency of results
• Imprecision of results
• High probability of publication bias
We provided justification in the footnotes when we downgraded
the quality from ’high’.
Subgroup analysis and investigation of heterogeneity
We planned to perform the following subgroup analyses, if possi-
ble.
• Participants with different age, sex, and stroke severity
• Different classes of antithrombotic drugs
• Different intensities of antithrombotic treatment
• Different times of starting treatment (e.g. within one
month of ICH versus later, or within 10 to 30 weeks or later)
• Participants who were on antithrombotic treatment before
ICH (re-starters) versus participants who were not receiving
these treatments (starters)
• Different levels of risk for future ischaemic events (for
example, because of differences in age, sex, history of
hypertension, history of atrial fibrillation (with further
stratification by the CHA2DS2-Vasc score))
• Different levels of risk for future ICH
• Biomarkers of bleeding or clotting risk on brain CT or
MRI (e.g. brain microbleeds on MRI)
Sensitivity analysis
If the results were heterogeneous, we planned to use sensitivity
analysis to investigate how the results differed when we excluded
RCTs that were found to have a high risk of bias. We planned to
perform other sensitivity analyses to explore reasons for hetero-
geneity, for example, where there is an active therapy other than
an antithrombotic drug that is not balanced by the randomisation
process.
R E S U L T S
Description of studies
We included two RCTs (see Included studies), excluded seven
RCTs (see Excluded studies), and identified seven ongoing RCTs
(see Ongoing studies). For comprehensive tabulated descrip-
tions of included, excluded, and ongoing studies please refer to
Characteristics of included studies, Characteristics of excluded
studies, and Characteristics of ongoing studies.
Results of the search
Our searches of CENTRAL, Embase, and OVID MEDLINE
identified 331, 2557, and 850 potentially relevant records, re-
spectively. Automated de-duplication identified 904 redundant
records, leaving 2834 unique and potentially relevant records. We
screened the titles and abstracts of these 2834 records and assessed
the full texts of nine relevant records for inclusion (Boeer 1991;
CAST 1997; Dickmann 1988; Frontera 2014; IST 1997; Li 2013;
Orken 2009; Venturelli 2014; Yan 2014). We included two RCTs
in our review (Dickmann 1988; Orken 2009). A reference search
of included RCTs yielded no further relevant records. See Figure
1 for a graphical representation of our search.
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Figure 1. Study flow diagram.
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The search of trials registries for ongoing RCTs identified three rel-
evant RCTs: APACHE-AF; PICASSO; RESTART, and we were
aware of four additional RCTs from personal communication
with investigators (NASPAF-ICH; RESTART Nord de France;
SoSTART; STATICH).
Included studies
Dickmann 1988 was a German single-centre study that excluded
patients if they had a bleeding diathesis, a sustained diastolic blood
pressure higher than 120 mmHg or were in deep coma with signs
of brain herniation, and retained 46 participants for inclusion.
Orken 2009 was a Turkish single-centre study that started with
110 ICH patients and applied the following exclusion criteria:
early death before heparin treatment (n = 13), death before day
7 investigations (n = 4), secondary ICH due to aneurysm, arte-
riovenous malformations, trauma, or tumour (n = 11), excessive
anticoagulation (International normalised ratio (INR) > 2.0) (n =
5), and contraindication to contrast media (n = 2). This left 75
participants for inclusion.
Both of the included RCTs included participants with ICH diag-
nosed by CT. Orken 2009 specified that these were primary ICH,
whereasDickmann 1988 did not specify the type of ICH included.
Dickmann 1988 used 5000 units of heparin (Liquemin-Roche)
delivered subcutaneously every eight hours starting at day four af-
ter ICH.Orken 2009 used 40mg/day of enoxaparin sodiumdeliv-
ered subcutaneously after the first 48 hours from ICH onset. The
intervention and comparator groups of both RCTs received grad-
uated compression stockings. Dickmann 1988 reported on other
major ischaemic events, and vascular death from other causes, al-
though did not specifically define these outcomes. Orken 2009
reported on othermajor ischaemic events, ICH, and major extrac-
erebral haemorrhage. Both of the included RCTs provided short-
term outcome data only. Dickmann 1988 had a follow-up period
of 10 days and Orken 2009 had a follow-up period of 21 days.
Excluded studies
We excluded seven studies for not meeting the inclusion criteria
of this review after having screened their full texts.
Boeer 1991 was an extension phase of Dickmann 1988 and ran-
domisation was not described, leading to its exclusion from this
review. CAST 1997 and IST 1997 were two RCTs investigating
the use of antiplatelet treatment after acute ischaemic stroke, and
included several hundred participants with ICH who were ran-
domised before CT had been performed to establish the patho-
logical sub-type of stroke. Data on the ICH sub-population of
these studies were reported in a systematic review (Keir 2002) and
the individual patient data from IST 1997 (Sandercock 2011).
These sources reported that this population included primary
ICH (52%) and haemorrhagic transformation of ischaemic stroke
(48%), but unfortunately the chief investigator informed us that it
would be impossible to isolate the participants with primary ICH
(IST 1997). Frontera 2014 was excluded because it was not ran-
domised. Li 2013 assessed transfusion of frozen apheresis platelets
in patients with ICH and on aspirin. Venturelli 2014 was a post
hoc analysis of a RCT in which antithrombotic treatment was not
randomly assigned, making this analysis observational in nature.
Yan 2014 included a population of patients with andwithout cere-
bral microbleeds after acute ischaemic stroke.
Risk of bias in included studies
We assessed risks of bias for both includedRCTs (Dickmann 1988;
Orken 2009). Please refer to Figure 2 and Figure 3 for graphical
depictions of this analysis.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
Both Dickmann 1988 and Orken 2009 were reported to be ran-
domised but neither RCT described the method of randomisa-
tion, and neither RCT described the method of allocation con-
cealment. We therefore determined both RCTs to be at unclear
risk of selection bias.
Blinding
Due to the nature of the intervention (subcutaneous injection),
and lack of placebo, blinding of participants and the personnel
delivering the interventionwas not possible. BothDickmann 1988
and Orken 2009 were therefore at high risk of performance bias.
Dickmann 1988 explicitly mentioned blinding of outcome raters
and was at low risk of detection bias. Orken 2009 reported that
radiologists were blinded to the clinical baseline radiological find-
ings, but did not explicitly mention blinding of treatment alloca-
tion and was therefore at unclear risk of detection bias.
Incomplete outcome data
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Outcome data were complete in both included RCTs, which were
both rated at low risk of attrition bias.
Selective reporting
Both Dickmann 1988 and Orken 2009 reported all outcomes
planned in their respective Methods sections, and each reported
most expected outcomes of interest. Both included RCTs were
therefore at low risk of reporting bias.
Other potential sources of bias
Neither Dickmann 1988 nor Orken 2009 described conflicts of
interest or sources of funding. Neither study was prospectively
registered. Both were therefore at an unclear risk of other potential
sources of bias.
Effects of interventions
See: Summary of findings for the main comparison
Antithrombotic treatment compared to no antithrombotic
treatment for intracerebral haemorrhage
Short-term antithrombotic treatment
We included two RCTs for this comparison (Dickmann 1988;
Orken 2009). We were able to extract numerical data on some of
the relevant outcomes.
Composite outcome of all serious vascular events
We were unable to calculate the composite vascular endpoint for
either Dickmann 1988 or Orken 2009 (Analysis 1.1).
Death
Only one RCT reported death from all causes (Dickmann 1988).
The causes of death in this RCT were rebleeding (4), bronchop-
neumonia (4), and heart failure (1). There was no statistically sig-
nificant difference between the intervention and control groups
for this outcome (risk ratio (RR) 1.25, 95% confidence interval
(CI) 0.38 to 4.07; Analysis 1.2; 46 participants).
Vascular death
Only one RCT reported deaths, but it did not adequately report
in which group (control/intervention) instances of death from
bronchopneumonia (4) and heart failure (1) occurred (Dickmann
1988). Because death fromheart failure constitutes a vascular death
and it was unclear in which group this death occurred, we were
unable to include data for this outcome. However, it was reported
that three deaths from expansion of the haematoma occurred in
the control group and one such death occurred in the intervention
group.
Ischaemic stroke
This outcome was not reported by either Dickmann 1988 or
Orken 2009.
Myocardial infarction
This outcome was not reported by either Dickmann 1988 or
Orken 2009.
Other major ischaemic event
Both included RCTs reported other major ischaemic events
(Dickmann 1988; Orken 2009). All events for this outcome
were pulmonary embolism detected by CT pulmonary angiogram
(Orken 2009) or lung perfusion scintigraphy (Dickmann 1988).
We combined results in a meta-analysis (Analysis 1.6), and de-
tected no statistically significant difference between groups (RR
0.54, 95% CI 0.23 to 1.28; 121 participants). The results of this
analysis are limited by the different methods of detecting pul-
monary emboli used by each study group.
Intracerebral haemorrhage
OneRCT involving 75 participants reported this outcome (Orken
2009). There were no recorded events in either group.
Major extracerebral haemorrhage
OneRCT involving 75 participants reported this outcome (Orken
2009). There were no recorded events in either group.
Growth of ICH
Both of the included studies reported on ICH growth. Dickmann
1988 had an ambiguous definition for this outcome, ’rebleeding’,
which we considered to refer to ICH growth (whether this was due
to continued bleeding, or recurrent ICH after cessation of the first
ICH). This study did not describe a threshold of increased volume
above which ICH growth was deemed to occur, and conducted
brain CTs on days 1, 6, and 10 after ICH. Orken 2009 defined
ICH growth as an increase in volume on CT of more than 33% or
more than 12.5 mL using the ABC/2method (Kothari 1996), and
checked for this outcome on follow-up brain CTs at 24 hours, 72
hours, day 7, and day 21 after ICH.We combined the results from
these two RCTs in a meta-analysis (Analysis 1.9), and observed no
statistically significant differences between groups (RR 1.64, 95%
CI 0.51 to 5.29; 121 participants).
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Deep vein thrombosis
Both included studies reported on the outcome of deep vein
thrombosis (DVT). All events for this outcome were DVT de-
tected by phleboscintigraphy at days 2 and 10 (Dickmann 1988)
or by venous doppler ultrasound examination on day 7 (Orken
2009). All events reported in Orken 2009 were asymptomatic,
whereas Dickmann 1988 did not specify whether events were
symptomatic or not. We detected no statistically significant dif-
ference between groups for this outcome (RR 0.99, 95% CI 0.49
to 1.96; Analysis 1.10; 121 participants).
Functional status
This outcome was not reported by either Dickmann 1988 or
Orken 2009.
Cognitive status
This outcome was not reported by either Dickmann 1988 or
Orken 2009.
Long-term antithrombotic treatment
We did not find any completed RCTs that investigated long-term
antithrombotic treatment.
D I S C U S S I O N
Summary of main results
We found some evidence on the short-term effects of antithrom-
botic drugs after ICH in two RCTs (Dickmann 1988; Orken
2009), but no evidence on the effects of long-term antithrom-
botic treatment. We were unable to calculate the composite pri-
mary outcome of all serious vascular events due to incompleteness
of reporting of the component outcomes in the included RCTs
(Dickmann 1988; Orken 2009). None of the outcomes reported
showed a statistically significant difference between groups, possi-
bly because the two included RCTs were inadequately powered to
detect significant differences for our outcomes. Neither included
RCT reported outcomes for ischaemic stroke, myocardial infarc-
tion, functional status, or cognitive status. We were unable to ex-
tract data on any prespecified subgroups.
Overall completeness and applicability of
evidence
The evidence available from completed RCTs of short-term an-
tithrombotic drug treatment after ICH is sparse. Data from the
two included RCTs contribute moderately applicable evidence to
this field; their inclusion criteria and settings are representative
of typical ICH patients. The applicability of Dickmann 1988 is
somewhat limited by waiting to start treatment until after day four
following ICH onset; one implication might be that some of the
potential effects of subcutaneous heparin, for example those on
ICH growth, never manifested. There is no comparative evidence
on the differences between distinct types of anticoagulants used in
this setting. Dickmann 1988 investigated the effects of heparin,
whereas Orken 2009 used enoxaparin sodium, a low-molecular-
weight heparin.
However, we were encouraged to find that there are seven ongo-
ing RCTs investigating long-term antithrombotic treatment af-
ter ICH (APACHE-AF; PICASSO; NASPAF-ICH; RESTART;
RESTART Nord de France; SoSTART; STATICH).
Quality of the evidence
The methodological quality of the included RCTs was limited by
randomisation and allocation concealment not being described,
failure to blind participants, and the optimal information size cri-
terion not being met. The overall quality of evidence was therefore
low. Both studies, despite investigating different drugs and start-
ing treatment at different times, found no statistically significant
difference between groups for outcomes relevant to this review.
It is possible that this is due to these RCTs being inadequately
powered to detect statistically meaningful differences, rather than
there being no effect of the interventions.
Potential biases in the review process
None identified.
Agreements and disagreements with other
studies or reviews
We identified two systematic reviews on short-term antithrom-
botic treatment (Keir 2002; Paciaroni 2011). Keir 2002 included
data from three RCTs (CAST 1997; Dickmann 1988; IST 1997)
and included individual patient data from IST 1997 and CAST
1997 on participants with both primary ICH (52%) as well as
haemorrhagic transformation of ischaemic infarcts (48%), but did
not describe results for these groups separately. Keir 2002 pre-
ceded Orken 2009, a study which we included in this review. The
second systematic review we identified included non-randomised
controlled studies (Paciaroni 2011). The non-randomised studies
included in this review were Wasay 2008 and Tetri 2008. This
review concluded that early antithrombotic treatment was associ-
ated with a significant reduction in pulmonary embolism, a non-
significant reduction in mortality, and a non-significant increase
in haemorrhagic expansion (Paciaroni 2011). We identified one
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systematic review on long-term antithrombotic use after ICH, but
it could not draw any conclusions from the two epidemiological
studies and several case series that it included (Flynn 2010b).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The available evidence from two RCTs of short-term parenteral
anticoagulation after ICH neither support nor discourage the use
of short-term antithrombotic treatment after ICH.
There are no published RCTs on long-term antithrombotic treat-
ment after ICH, but seven RCTs are ongoing at the time of this
review.
At the present time, clinicians will have to use other sources of
information to support clinical judgements.
Implications for research
Research on the use of antithrombotic drugs after ICH repre-
sents an area of unmet need for patients, clinicians, and other
consumers. These data suggest that further high-quality RCTs are
needed. For short-term antithrombotic use, future studies should
consider functional outcome and quality of life in addition to
clinical outcomes, such as ischaemic events, haemorrhagic events,
or death. For long-term antithrombotic use, future RCTs should
consider investigating the relative effectiveness and safety of differ-
ent antithrombotic drugs, for example warfarin, aspirin, and the
direct oral anticoagulants.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Dickmann 1988
Methods RCT
Duration: 10 days
Design: parallel
Setting: inpatient unit in Germany
Dates: not described
Participants 46 participants
Diagnosis: intracerebral haemorrhage
Diagnosis model: cranial CT
Eligibility criteria: diagnosis of ICH in the previous 24 hours before admission
Exclusion criteria: bleeding diathesis, diastolic blood pressure higher than 120 mmHg,
and deep coma with clinical signs of brain herniation
Age (years, mean (SD)): 62 (SD not described) (intervention group), 60 (SD not de-
scribed) (control group)
Sex: 52% female (intervention group), 48% female (control group)
Interventions 1. 5000 units of heparin administered subcutaneously 8-hourly starting at day 4 (n =
23)
2. 5000 units of heparin subcutaneously 8-hourly starting at day 10 (n = 23)
Both groups had the same treatment otherwise, with compression stockings and physical
treatment
Outcomes Rebleeding occurring during the trial period
Thrombosis of abdomen or legs at day 2 and day 10
Pulmonary embolism at day 10
Death during the trial period
Notes Rebleeding is not defined by the authors of this study and could mean multiple things.
Conflicts of interest and sources of funding were not described
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method of randomisation was not de-
scribed
Allocation concealment (selection bias) Unclear risk Allocation concealment was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blindingwas not possible due to the control
group not receiving a placebo injection
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Dickmann 1988 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “All scintigrams were read by the same
blinded investigators”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data were complete
Selective reporting (reporting bias) Low risk All outcomes planned in the Methods sec-
tion were reported in full in the Results sec-
tion. Additionally,most expected outcomes
of interest were reported in this study
Other bias Unclear risk To our knowledge this study was not
prospectively registered
Orken 2009
Methods RCT
Duration: 21 days
Design: parallel
Setting: inpatient unit in Turkey
Dates: between January 2006 and March 2008
Participants 75 participants
Diagnosis: intracerebral haemorrhage
Diagnosis model: cranial CT
Eligibility criteria: diagnosis of primary ICH
Exclusion criteria: early death before heparin treatment, death before 7th day investi-
gations, secondary ICH due to aneurysm, arteriovenous malformations, traumas and
tumours. Excessive anticoagulation (INR > 2.0). Contraindication to contrast agents
Age (years, mean (SD)): 68.1 (11.98) (intervention group) 66.08 (9.55) (control group)
Sex: 56% female (intervention group), 22% female (control group)
Additonal details: mean National Institutes of Health Stroke Scale scores on admission
for the LMWH group was 9.74 ± 6.06 and for the compression stocking group was
8.61 ± 6.87. 32/39 participants in the LMWH group and 29/36 participants in the
compression stocking group had hypertension identified as a risk factor for ICH. 11
participants from the LMWH group and 6 from the compression stocking group had
had a prior cerebrovascular accident
Interventions 1. Enoxaparin sodium 48 mg/day (n = 39)
2. Compression stocking control (n = 36)
Treatment began after the first 48 hours from hospital admission
Outcomes Haematoma enlargement at 72 hours, 7 days and 21 days. Haematoma enlargement was
defined as an increase in volume of > 33% or 12.5 mL
Systemic bleeding complications
DVT or PE based on CTPA and bilateral venous Doppler at 7 days
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Orken 2009 (Continued)
Notes Conflicts of interest and sources of funding were not described
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method of randomisation not de-
scribed
Allocation concealment (selection bias) Unclear risk Allocation concealment not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not possible due to 1 group receiv-
ing a subcutaneous injection and the other
group receiving compression stockings
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “All radiologic material was prospectively
evaluated by 2 radiologists ... who were
blinded to the clinical findings and cranial
CTs of the patients”. The methods did not
explicitly state that the radiologists were
also blinded to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data were complete
Selective reporting (reporting bias) Low risk All outcomes planned in the Methods sec-
tion were reported in full in the Results sec-
tion. Additionally,most expected outcomes
of interest were reported in this study
Other bias Unclear risk To our knowledge this study was not
prospectively registered
CT: computed tomography
CTPA: CT pulmonary angiography
DVT: deep vein thrombosis
ICH: intracerebral haemorrhage
INR: International normalised ratio
LMWH: low-molecular-weight heparin
PE: pulmonary embolism
RCT: randomised controlled trial
SD: standard deviation
21Antithrombotic treatment after stroke due to intracerebral haemorrhage (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Boeer 1991 This is an extension phase of Dickmann 1988 that introduces non-randomised data to the previously published
data
CAST 1997 This trial included some people with ICH who were randomised prior to CT. These data were not available in the
original manuscript. We had hoped that there would be useable data published in the Keir 2002 systematic review,
but this did not separate primary ICH from haemorrhagic transformations of acute ischaemic stroke and we were
therefore unable to include data from CAST 1997 in this review.
Frontera 2014 This is a controlled clinical trial that was not randomised.
IST 1997 This trial included several hundred participants with ICH who were randomised prior to CT. These data were not
available in the original manuscript. We had hoped that data from the Keir 2002 systematic review or the published
individual data forms (Sandercock 2011) would yield useable data for this review, but Keir 2002 did not report
primary ICH separately from haemorrhagic expansion of an acute ischaemic stroke, and after contacting the chief
investigator of IST 1997 we discovered that it was not possible to extract data on primary ICH separately
Li 2013 The intervention randomised in this study is transfusion of frozen apheresis platelets in participants on aspirin and
with ICH
Venturelli 2014 This is a post hoc analysis of the INTERACT2 trial. The intervention that is the subject of this analysis, prophy-
lactic subcutaneous heparin after ICH, was not randomly assigned in INTERACT2. Therefore, this analysis is
observational in nature
Yan 2014 The participant group did not have primary ICH; it was a cohort of people with and without cerebral microbleeds
and haemorrhagic transformation, with acute ischaemic stroke following rtPA treatment
CT: computed tomography
ICH: intracerebral haemorrhage
rtPA: Recombinant tissue plasminogen activator
Characteristics of ongoing studies [ordered by study ID]
APACHE-AF
Trial name or title Apixaban versus antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intracerebral
haemorrhage in patients with atrial fibrillation (APACHE-AF)
Methods Allocation: randomised
Blinding: open-label (none)
Duration: 12 to 30 months
Setting: multicentre trial across the Netherlands
Dates: September 2014 and currently recruiting
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APACHE-AF (Continued)
Participants Inclusion criteria
• ICH (including isolated spontaneous intraventricular haemorrhage), documented with CT or MRI,
during treatment with anticoagulation (VKA, any direct thrombin inhibitor, any factor Xa inhibitor, or
(low- molecular-weight) heparin at a therapeutic dose)
• Haemorrhage occurred between 7 and 90 days before randomisation
• Diagnosis of (paroxysmal) non-valvular AF, documented on electrocardiography
• A CHA2DS2-VASc score ≥ 3
• Score on the mRS ≤ 4
• Equipoise regarding the optimal medical treatment for the prevention of stroke
• Age ≥ 18 years
• Written informed consent by the participant or by a legal representative
Exclusion criteria
• Conditions other than AF for which the participant requires long-term anticoagulation
• A different clinical indication for the use of an antiplatelet drug even if treated with apixaban, such as
clopidogrel for recent coronary stenting
• Mechanical prosthetic heart valve (biological prosthetic heart valves are allowed) or rheumatic mitral
valve disease
• Serious bleeding event in the previous 6 months, except for ICH
• High risk of bleeding (e.g. active peptic ulcer disease, a platelet count of < 100,000 mL-1 or
haemoglobin level of < 6.2 mMol.L-1, ischaemic stroke in the previous 7 days (participants are eligible
thereafter), documented haemorrhagic tendencies, or blood dyscrasias)
• Current alcohol or drug abuse
• Life expectancy of < 1 year
• Severe renal insufficiency (a serum creatinine level of more than 221 µmol per litre or a calculated
creatinine clearance of < 15 ml per minute)
• Alanine aminotransferase or aspartate aminotransferase level > 2 times the upper limit of the normal
range or a total bilirubin > 1.5 times the upper limit of the normal range, unless a benign causative factor (e.
g. Gilbert’s syndrome) is known or identified
• Allergy to apixaban
• Use of strong cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) inhibitors (e.g. systemic
azole-antimycotics as ketoconazole or HIV protease inhibitors such as ritonavir)
• Pregnant or breastfeeding
• Women of childbearing potential: any woman who has begun menstruation and is not
postmenopausal or otherwise permanently unable to conceive. A postmenopausal woman is defined as a
woman who is over the age of 45 and has not had a menstrual period for at least 12 months
Interventions Participants will be randomised into 6 groups
• apixaban
• aspirin
• carbasalate calcium
• clopidogrel
• dipyridamole
• no antithrombotic treatment
Each of the groups will run in parallel
Outcomes Primary outcome measures
• Number of participants who experience the combination of vascular death or non-fatal stroke (cerebral
infarction, intracerebral haemorrhage, or subarachnoid haemorrhage)
Secondary outcome measures: number of participants who experience:
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APACHE-AF (Continued)
• vascular death
• death from any cause
• all stroke
• ischaemic stroke
• intracerebral haemorrhage
• other major extracranial haemorrhage
• any intracranial haemorrhage other than ICH
• systemic embolism
• myocardial infarction
• a good functional outcome as assessed with the score on the mRS
Starting date September 2014
Contact information Contact: Koen M van Nieuwenhuizen, MD. Tel: +31 88 757 4097; email: k.m.vannieuwenhuizen-
3@umcutrecht.nl
Contact: H Bart van der Worp, MD PhD. Tel: +31 88 755 98 99; email: h.b.vanderworp@umcutrecht.nl
Notes
NASPAF-ICH
Trial name or title Non-VKAAnticoagulants for Stroke Prevention in Patients with Atrial Fibrillation and Previous IntraCerebral
Hemorrhage Study (NASPAF-ICH)
Methods Allocation: randomised 2:1 (non-vitamin K oral antagonist (agent at the discretion of the local investigator)
vs aspirin)
Blinding: open-label, blinded adjudication of outcomes
Duration: recruitment 24 months, participants will be followed to a common terminate date designated at 6
months following the end of recruitment. Average follow-up per participant approximately 12 months (range:
12 to 30 months)
Design (parallel, other): phase II, open-label randomised controlled trial
Setting: 10 high-volume stroke centres across Canada
Dates: January 2017 to June 2019
Participants Inclusion criteria
• 45 years of age or older
• prior spontaneous intraparenchymal or intraventricular haemorrhage
• High risk AF (CHADS2 ≥ 2)
Exclusion criteria
• Non-stroke indication for antiplatelet or anticoagulant therapy
• Estimated creatinine clearance of < 30 ml per minute
• Platelet count less than 100,000/mm3 at enrolment or other bleeding diathesis
• Uncontrollable hypertension with SBP/DBP consistently above 160/100 mmHg
• Prior symptomatic lobar ICH other than the qualifying event (i.e. ≥ 2 symptomatic lobar ICH)
• Known hypersensitivity to either aspirin or NOACs
• Pregnant or breastfeeding
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NASPAF-ICH (Continued)
Interventions Non-vitamin K oral antagonist (agent at the discretion of the local investigator) vs aspirin 81 mg
Strict long-term blood pressure control to target of < 130/80 mmHg for all participants
Outcomes Primary outcome measure: the primary feasibility outcome will be recruitment rates
Secondary outcomes will be refusal rates and retention rates
Starting date January 2017
Contact information Co-Prinicipal Investigator:
Ashkan Shoamanesh, MD, FRCPC
Assistant Professor of Medicine (Neurology)
Director, Stroke Fellowship Program
Marta and Owen Boris Chair in Stroke Research and Care
McMaster University / Population Health Research Institute
237 Barton Street East
HGH-DBCVSRI C4-118
Hamilton, Ontario, L8L 2X2, Canada
Email: ashkan.shoamanesh@phri.ca
Telephone: (905) 521-2100 ext 41277
Fax: (905) 577-1427
Notes
PICASSO
Trial name or title PreventIon of CArdiovascular Events in iSchemic Stroke patients with high risk of cerebral hemOrrhage
(PICASSO)
Methods Allocation: randomisation
Blinding: double-blinding (participant, caregiver, investigator, outcome assessor)
Duration: 1 to 5.5 years
Setting: multicentre trial across China, South Korea and the Philippines
Dates: June 2009 and ongoing
Participants Inclusion criteria
• People with TIA or ischaemic stroke within 180 days prior to screening - adult aged 20 years or older
• High risk of haemorrhagic stroke (history of intracranial haemorrhage or imaging evidence of previous
intracranial haemorrhage)
• Informed consent
Exclusion criteria
• Clinical diagnosis of myocardial infarction or coronary intervention within 4 weeks
• Bleeding tendency
• Pregnant or breastfeeding woman
• Haemorrhagic stroke within 6 months
• Person taking antithrombotic medication other than aspirin and not agreeing to change the previous
medication
• Severe cardiovascular disease such as cardiomyopathy or congestive heart failure
• Life expectancy < 1 year
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PICASSO (Continued)
• Contraindication to long-term aspirin use
• Enrolled in other clinical trial within 30 days
Interventions A factorial design across the following groups:
• cilostazol
• probucol
• aspirin
• placebo of cilostazol
• placebo of aspirin
Outcomes Primary outcome measures: time to first occurrence of:
• cerebral haemorrhage
• composite cardiovascular events
Secondary outcome measures: time to first occurrence of:
• stroke
• ischaemic stroke
• myocardial infarction
• other designated vascular events
Other outcome measures
• Incidence rate of major and non-major haemorrhagic event
• Rate of asymptomatic haemorrhage in GRE (microhaemorrhage or macrohaemorrhage)
• Rate of new asymptomatic cerebral infarction lesion in FLAIR
• Change of ankle-brachial index
• The effect of the size of CCA including plaque on the occurrence of cardiovascular events
• Time to all deaths including vascular and non-vascular death
• Incidence rate of dementia diagnosed after initiation of the trial
Starting date June 2009
Contact information Principal Investigator: Sun U Kwon, MD, PhD
Departement of Neurology, Asan Medical Center
Notes
RESTART
Trial name or title REstart or STop Antithrombotics Randomised Trial (RESTART)
Methods Allocation: randomised
Blinding: treatment is open-label, but outcome assessors are blinded
Duration: at least 6 months
Design: parallel
Setting: UK National Health Service (NHS) secondary care (inpatient and outpatient services in stroke,
neurology and neurosurgery) and primary care
Dates: May 2013 to May 2018 (recruitment), November 2018
Participants Inclusion criteria:
• Patient age ≥ 18 years.
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RESTART (Continued)
• Spontaneous primary or secondary ICH.
• Patient had taken antithrombotic drug(s) for the prevention of vaso-occlusive disease before ICH
onset. Randomisation > 24 hours after ICH onset.
• Patient and their doctor are uncertain about whether to start or avoid antiplatelet drugs.
• Patient is registered with a general practitioner (GP).
• Brain imaging that first diagnosed the ICH is available.
• Participant or representative consent.
Exclusion criteria:
• ICH due to preceding trauma or haemorrhagic transformation of ischaemic stroke.
• Patient is taking an anticoagulant drug following ICH.
• Patient is pregnant, breastfeeding, or of childbearing age and not taking contraception.
• Patient is being treated or followed up in another CTIMP.
• Patient and carer unable to understand spoken or written English.
Brain magnetic resonance imaging (MRI) sub-study: MRI done after ICH but before randomisation. No
claustrophobia. MRI not contraindicated
Interventions Participants will be randomised to either ’start antiplatelet medication’ (restricted to the use of 1 or more of
aspirin, dipyridamole or clopidogrel at the investigator’s discretion) or “avoid antiplatelet medication”
Outcomes Primary outcome measure: recurrent symptomatic ICH
Secondary outcome measures:
• possible recurrent ICH;
• symptomatic non-fatal extracerebral haemorrhage, extracranial haemorrhage, and vaso-occlusive
events; death;
• modified Rankin Scale score;
• adherence to antiplatelet drug(s)
Starting date April 2013
Contact information UK Chief Investigator: Rustam Al-Shahi Salman; Trial Manager: Karen Innes
RESTART.trial@ed.ac.uk.
Notes
RESTART Nord de France
Trial name or title RESTART Nord de France
Methods Allocation: randomisation 1:1 - restart vs no antiplatelet
Blinding: PROBE design
Duration: each participant will be followed up during year 2
Design (parallel, other): RCT 1:1
Setting: region North of France
Dates: start October 2016, recruitment 3 years, overall: 5 years
Participants Inclusion criteria
• Adult, no upper age limit
• Spontaneous ICH
• Randomisation at least 24 hours following the index ICH
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RESTART Nord de France (Continued)
• The participant and the doctor are uncertain about the net clinical benefit of restarting or not
antiplatelet agents
Exclusion criteria
• Traumatic ICH
• Secondary ICH
• MRI contra-indications
Interventions Restart antiplatelet agent vs no antiplatelet agent
Outcomes Primary outcome measure: recurrent ICH (fatal and non fatal)
Secondary outcome measures:
• Serious vascular events fatal (followed by death within 30 days) and non-fatal
• Symptomatic haemorrhagic events (excluding cerebrovascular)
• Symptomatic ischaemic events (cerebral and extracerebral)
• Stroke of undetermined nature
• Other fatal events
• Functional outcome at 2 years
• Incident brain microhaemorrhages on follow-up MRI at 1 year
Starting date October 2016
Contact information Contact information: Professor Charlotte Cordonnier
charlotte.cordonnier@chru-lille.fr
Notes
SoSTART
Trial name or title Start or STop Anticoagulants Randomised Trial
Methods Investigator-led, multicentre, randomised, open, assessor-masked, parallel group, clinical trial of investiga-
tional medicinal product (CTIMP) prescribing strategies. We plan for a pilot phase, followed by a main phase
Participants Inclusion criteria: spontaneous intracranial haemorrhage, AF and a CHA2DS2-VASc score ≥ 2
Exclusion criteria:
• Patient age < 18 years
• Intracranial haemorrhage within the last 24 hours
• Brain imaging that first diagnosed the intracranial haemorrhage is not available
• Intracranial haemorrhage is exclusively due to trauma or haemorrhagic transformation of ischaemic
stroke. Patient or their doctor is certain about whether to start or avoid full oral anticoagulation
• Patient is not registered with a general practitioner
• Patient is pregnant, breastfeeding, or of childbearing age and not taking contraception
• Patient and carer unable to understand spoken or written English
• Previously randomised in SoSTART
Brain MRI substudy: MRI must be done after intracranial haemorrhage but before randomisation. Substudy
participants must not have contraindications to MRI
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SoSTART (Continued)
Interventions • Start full OAC: (either a non-vitamin K antagonist DOAC or warfarin if a DOAC cannot be used),
chosen by the participant’s physician before randomisation
• Start antiplatelet drug(s) (if the participant has an indication for antiplatelet drugs) or avoid all
antithrombotic drugs (if the participant does not have an indication for antiplatelet drugs), specified by the
participant’s doctor before randomisation
Outcomes Primary outcome: all symptomatic serious vascular events (i.e. major adverse cardiac or cerebrovascular events:
MACCE) including non-fatal stroke, non-fatal acute coronary syndrome, vascular death, sudden death, or
death of unknown cause
Secondary outcomes:
• individual symptomatic vascular events;
• individual types of fatal events;
• dependence according to the mRS
Starting date 2017
Contact information Professor Rustam Al-Shahi Salman, University of Edinburgh, UK (Rustam.Al-Shahi@ed.ac.uk)
Notes Funded by Chest Heart and Stroke Scotland
STATICH
Trial name or title Study of Antithrombotic Treatment after Intracerebral Haemorrhage (STATICH)
Methods Allocation: randomised
Blinding: open, blinded endpoint
Duration: 2 years
Design : parallel
Setting: multicenter in Norway, Denmark, and Sweden
Dates: start up 2017
Participants Inclusion criteria:
• Spontaneous, primary ICH
• No preceding traumatic injury, no structural secondary underlying structural cause
• Indication for antithrombotic drug
• Uncertainty about whether to start or avoid antithrombotic drugs after ICH
• Patient age ≥ 18 years
• Patient is at least 24 hours after symptom onset
• Consent from patient or representative
Exclusion criteria:
• Absolute indication for anticoagulant treatment
• Patient is pregnant, breastfeeding or of childbearing age and not taking contraception
• Patient is being treated or followed up in another CTIMP
For MRI substudy: contraindication for MRI
Interventions Interventions for each group: the intervention is starting antithrombotic drug. The comparator is avoiding
antithrombotic drugs
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STATICH (Continued)
Outcomes Primary outcome measure: recurrent symptomatic ICH
Secondary outcome measures:
• complication of qualifying ICH;
• symptomatic extradural haemorrhage, subdural haemorrhage, subarachnoid haemorrhage;
• symptomatic major extracranial haemorrhage;
• symptomatic ischaemic events;
• cardiovascular death; death from any other cause;
• mRS
Starting date
Contact information Trial co-ordinating investigator: Eivind Berge, MD, PhD, email: eivind.berge@medisin.uio.no
Trial manager: Elisabeth Forfang, MD, email: elisabeth.forfang@medisin.uio.no
Notes
AF: atrial fibrillation
CCA: common carotid artery
CT: computed tomography
DBP: diastolic blood pressure
DOAC: direct oral anticoagulant
ICH: intracerebral haemorrhage
MRI: magnetic resonance imaging
mRS: modified Rankin Scale
NOAC: novel oral anticoagulant
OAC: oral anticoagulation
SBP: systolic blood pressure
TIA: transient ischaemic stroke
VKA: vitamin K antagonist
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D A T A A N D A N A L Y S E S
Comparison 1. Short-term antithrombotic treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
2 Death 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Other major ischaemic event 2 121 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.23, 1.28]
7 Intracerebral haemorrhage 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
8Major extracerebral haemorrhage 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
9 Growth of intracerebral
haematoma
2 121 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [0.51, 5.29]
10 Deep vein thrombosis 2 121 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.49, 1.96]
Analysis 1.2. Comparison 1 Short-term antithrombotic treatment, Outcome 2 Death.
Review: Antithrombotic treatment after stroke due to intracerebral haemorrhage
Comparison: 1 Short-term antithrombotic treatment
Outcome: 2 Death
Study or subgroup Experimental Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dickmann 1988 5/23 4/23 1.25 [ 0.38, 4.07 ]
0.01 0.1 1 10 100
Favours treatment Favours no treatment
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Analysis 1.6. Comparison 1 Short-term antithrombotic treatment, Outcome 6 Other major ischaemic
event.
Review: Antithrombotic treatment after stroke due to intracerebral haemorrhage
Comparison: 1 Short-term antithrombotic treatment
Outcome: 6 Other major ischaemic event
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dickmann 1988 5/23 9/23 81.2 % 0.56 [ 0.22, 1.41 ]
Orken 2009 1/39 2/36 18.8 % 0.46 [ 0.04, 4.88 ]
Total (95% CI) 62 59 100.0 % 0.54 [ 0.23, 1.28 ]
Total events: 6 (Experimental), 11 (Control)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours treatment Favours no treatment
Analysis 1.7. Comparison 1 Short-term antithrombotic treatment, Outcome 7 Intracerebral haemorrhage.
Review: Antithrombotic treatment after stroke due to intracerebral haemorrhage
Comparison: 1 Short-term antithrombotic treatment
Outcome: 7 Intracerebral haemorrhage
Study or subgroup Experimental Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Orken 2009 0/39 0/36 Not estimable
0.01 0.1 1 10 100
Favours treatment Favours no treatment
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Analysis 1.8. Comparison 1 Short-term antithrombotic treatment, Outcome 8 Major extracerebral
haemorrhage.
Review: Antithrombotic treatment after stroke due to intracerebral haemorrhage
Comparison: 1 Short-term antithrombotic treatment
Outcome: 8 Major extracerebral haemorrhage
Study or subgroup Experimental Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Orken 2009 0/39 0/36 Not estimable
0.01 0.1 1 10 100
Favours treatment Favours no treatment
Analysis 1.9. Comparison 1 Short-term antithrombotic treatment, Outcome 9 Growth of intracerebral
haematoma.
Review: Antithrombotic treatment after stroke due to intracerebral haemorrhage
Comparison: 1 Short-term antithrombotic treatment
Outcome: 9 Growth of intracerebral haematoma
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dickmann 1988 1/23 1/23 24.3 % 1.00 [ 0.07, 15.04 ]
Orken 2009 6/39 3/36 75.7 % 1.85 [ 0.50, 6.84 ]
Total (95% CI) 62 59 100.0 % 1.64 [ 0.51, 5.29 ]
Total events: 7 (Experimental), 4 (Control)
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours treatment Favours no treatment
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Analysis 1.10. Comparison 1 Short-term antithrombotic treatment, Outcome 10 Deep vein thrombosis.
Review: Antithrombotic treatment after stroke due to intracerebral haemorrhage
Comparison: 1 Short-term antithrombotic treatment
Outcome: 10 Deep vein thrombosis
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dickmann 1988 8/23 10/23 90.6 % 0.80 [ 0.39, 1.66 ]
Orken 2009 3/39 1/36 9.4 % 2.77 [ 0.30, 25.43 ]
Total (95% CI) 62 59 100.0 % 0.99 [ 0.49, 1.96 ]
Total events: 11 (Experimental), 11 (Control)
Heterogeneity: Chi2 = 1.15, df = 1 (P = 0.28); I2 =13%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours treatment Favours no treatment
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MESH DESCRIPTOR Basal Ganglia Hemorrhage EXPLODE ALL TREES
#2 MESH DESCRIPTOR Intracranial Hemorrhages
#3 MESH DESCRIPTOR Intracranial Hemorrhage, Hypertensive
#4 MESH DESCRIPTOR Cerebral Hemorrhage
#5 (brain* or cerebr* or cerebell* or intracerebral or intracran* or parenchymal or
intraparenchymal or intraventricular or infratentorial or supratentorial or putaminal or putamen or
hemispher* or stroke or apoplex*):TI
#6 (basal and gangli*):TI
#7 (posterior and fossa):TI,AB,KY
#8 (haemorrhag* or hemorrhag* or haematoma* or hematoma* or bleed*):TI
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#9 #5 or #6 or #7 and #8
#10 (ICH or ICHs):TI
#11 #1 or #2 or #3 or #4 or #9 or #10
#12 MESH DESCRIPTOR Anticoagulants EXPLODE ALL TREES
#13 MESH DESCRIPTOR Pipecolic Acids EXPLODE ALL TREES WITH QUALIFIERS AE,TU
#14 MESH DESCRIPTOR Vitamin K EXPLODE ALL TREES
#15 MESH DESCRIPTOR Thrombin EXPLODE ALL TREES WITH QUALIFIERS AI
#16 MESH DESCRIPTOR Factor Xa
#17 MESH DESCRIPTOR Blood Coagulation Factors EXPLODE ALL TREES WITH QUALIFIERS AI
#18 MESH DESCRIPTOR Blood Coagulation EXPLODE ALL TREES WITH QUALIFIERS DE
#19 MESH DESCRIPTOR Antithrombins EXPLODE ALL TREES
#20 MESH DESCRIPTOR Hirudin Therapy EXPLODE ALL TREES
#21 (anticoagul* or antithromb*):TI,AB,KY
#22 (Vitamin next K next antagonist*):TI,AB,KY
#23 (VKA or VKAs):TI,AB,KY
#24 #22 or #23
#25 (direct* NEAR5 thrombin):TI,AB,KY
#26 “DTI”:TI,AB,KY
#27 (factor next Xa NEAR5 inhib*):TI,AB,KY
#28 (factor next 10a NEAR5 inhib*):TI,AB,KY
#29 (fXa NEAR5 inhib*):TI,AB,KY
#30 (autoprothrombin NEAR5 inhib*):TI,AB,KY
#31 (thrombokinase NEAR5 inhib*):TI,AB,KY
#32 (acenocoumarol* or dicoumarol* or ethyl next biscoumacetate* or phenprocoumon* or
warfarin* or ancrod* or citric next acid* or coumarin* or chromonar* or coumestro* or esculi* or
ochratoxin* or umbelliferone* or dermatan next sulfate* or dextran* or edetic next acid* or
enoxaparin* or gabexate* or heparin* or lmwh* or nadroparin* or pentosan next sulfuric next
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polyester* or phenindione* or protein next c or protein next s or tedelparin*):TI,AB,KY
#33 (tinzaparin or parnaparin or dalteparin or reviparin or danaparoid or lomoparan or org next
10172 or mesoglycan or polysaccharide next sulphate* or sp54 or sp-54 or md805 or md-805 or
cy222 or cy-222 or cy216 or cy-216):TI,AB,KY
#34 (Marevan or Fragmin* or Fraxiparin* or Klexane):TI,AB,KY
#35 (argatroban or MD805 or MD-805 or dabigatran or ximelagatran or melagatran or efegatran
or flovagatran or inogatran or napsagatran or bivalirudin or lepirudin or hirudin* or desirudin or
desulfatohirudin or hirugen or hirulog or AZD0837 or bothrojaracin or odiparcil):TI,AB,KY
#36 (xabans or antistasin or apixaban or betrixaban or du next 176b or eribaxaban or
fondaparinux or idraparinux or otamixaban or razaxaban or rivaroxaban or yagin or ym next 150 or
ym150 or LY517717):TI,AB,KY
#37 #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36
#38 MESH DESCRIPTOR Platelet Glycoprotein GPIIb-IIIa Complex EXPLODE ALL TREES WITH
QUALIFIERS AI,DE
#39 MESH DESCRIPTOR Platelet Activation EXPLODE ALL TREES WITH QUALIFIERS DE
#40 MESH DESCRIPTOR Blood Platelets EXPLODE ALL TREES WITH QUALIFIERS DE
#41 (antiplatelet* or anti-platelet* or antiaggreg* or anti-aggreg* or (platelet* NEAR5 inhibit*)
or (thrombocyt* NEAR5 inhibit*)):TI,AB,KY
#42 (alprostadil* or aspirin* or acetylsalicylic next acid or (acetyl ADJ salicylic and acid*) or
(acetyl-salicylic and acid or epoprostenol* or ketanserin* or ketorolac next tromethamine* or
milrinone* or mopidamol* or procainamide* or thiophen* or trapidil* or picotamide* or
ligustrazine* or levamisol* or suloctidil* or ozagrel* or oky046 or oky-046 or defibrotide* or
cilostazol or satigrel or sarpolgrelate or kbt3022 or kbt-3022 or isbogrel or cv4151 or cv-
4151)):TI,AB,KY
#43 ((glycoprotein next iib* near/5 inhib*) or (glycoprotein next iib* near/5 antag*) or (gp next
iib* near/5 inhib*) or (gp next iib* near/5 antag*) or GR144053 or GR-144053 or triflusal):TI,AB,KY
#44 (Argatroban or Beraprost or Cicaprost or Cilostazol or Clopidogrel or Dipyridamole or
Iloprost or Indobufen or Lepirudin or Pentosan next Polysulfate or Pentoxifylline or Piracetam or
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Prostacyclin or Sulfinpyrazone or Sulphinpyrazone or Ticlopidine or Triflusal or Abciximab or
Disintegrin or Echistatin or Eptifibatide or Lamifiban or Orbofiban or Roxifiban or Sibrafiban or
Tirofiban or Xemilofiban or terutroban or picotamide or prasugrel):TI,AB,KY
#45 (Dispril or Albyl* or Ticlid* or Persantin* or Plavix or ReoPro or Integrilin* or Aggrastat):TI,AB,KY
#46 MESH DESCRIPTOR Platelet Aggregation Inhibitors EXPLODE ALL TREES
#47 #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46
#48 #37 or #47
#49 #48 and #11
Appendix 2. MEDLINE search strategy
1. exp basal ganglia haemorrhage/ or intracranial hemorrhages/ or cerebral haemorrhage/ or intracranial haemorrhage, hypertensive/
2. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or intraparenchymal or intraventricular or infratentorial
or supratentorial or basal gangli$ or putaminal or putamen or posterior fossa or hemispher$) adj5 (h?emorrhag$ or h?ematoma$ or
bleed$)).tw.
3. ((h?emorrhag$ or bleed$) adj5 (stroke or apoplex$)).tw.
4. (ICH or ICHs).tw.
5. 1 or 2 or 3 or 4
6. exp anticoagulants/
7. exp Vitamin K/ai or thrombin/ai or factor Xa/ai or exp Blood coagulation factors/ai
8. exp antithrombins/ or hirudin therapy/
9. (anticoagul$ or antithromb$).tw.
10. (Vitamin K antagonist$ or VKA or VKAs).tw.
11. (direct$ adj3 thrombin adj3 inhib$).tw.
12. DTI$1.tw.
13. ((factor Xa or factor 10a or fXa or autoprothrombin c or thrombokinase) adj3 inhib$).tw.
14. (activated adj3 (factor X or factor 10) adj3 inhib$).tw.
15. (acenocoumarol$ or dicoumarol$ or ethyl biscoumacetate$ or phenprocoumon$orwarfarin$or ancrod$ or citric acid$ or coumarin$
or chromonar$ or coumestro$ or esculi$ or ochratoxin$ or umbelliferone$ or dermatan sulfate$ or dextran$ or edetic acid$ or
enoxaparin$ or gabexate$ or heparin$ or lmwh$ or nadroparin$ or pentosan sulfuric polyester$ or phenindione$ or protein c or protein
s or tedelparin$).tw,nm.
16. (tinzaparin or parnaparin or dalteparin or reviparin or danaparoid or lomoparan or org 10172 or mesoglycan or polysaccharide
sulphate$ or sp54 or sp-54 or md805 or md-805 or cy222 or cy-222 or cy216 or cy-216).tw,nm.
17. (Marevan or Fragmin$ or Fraxiparin$ or Klexane).tw,nm.
18. (argatroban or MD805 or MD-805 or dabigatran or ximelagatran or melagatran or efegatran or flovagatran or inogatran or
napsagatran or bivalirudin or lepirudin or hirudin$ or desirudin or desulfatohirudin or hirugen or hirulog or AZD0837 or bothrojaracin
or odiparcil).tw,nm.
19. (xabans or antistasin or apixaban or betrixaban or du 176b or eribaxaban or fondaparinux or idraparinux or otamixaban or razaxaban
or rivaroxaban or yagin or ym 150 or ym150 or LY517717).tw,nm.
20. exp platelet aggregation inhibitors/ or exp platelet glycoprotein gpiib-iiia complex/ai
21. (antiplatelet$ or anti-platelet$ or antiaggreg$ or anti-aggreg$ or (platelet$ adj3 inhibit$) or (thrombocyt$ adj3 inhibit$)).tw.
22. (alprostadil$ or aspirin$ or acetylsalicylic acid or acetyl salicylic acid$ or acetyl?salicylic acid or epoprostenol$ or ketanserin$ or
ketorolac tromethamine$ or milrinone$ or mopidamol$ or procainamide$ or thiophen$ or trapidil$ or picotamide$ or ligustrazine$
or levamisol$ or suloctidil$ or ozagrel$ or oky046 or oky-046 or defibrotide$ or cilostazol or satigrel or sarpolgrelate or kbt3022 or
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kbt-3022 or isbogrel or cv4151 or cv-4151 or ((glycoprotein iib$ or gp iib$) adj5 (antagonist$ or inhibitor$)) or GR144053 or GR-
144053 or triflusal).tw,nm.
23. (Beraprost or Cicaprost or Cilostazol or Clopidogrel or Dipyridamole or Iloprost or Indobufen or Lepirudin or Pentosan Polysulfate
or Pentoxifylline or Piracetam or Prostacyclin or Sulfinpyrazone or Sulphinpyrazone or Ticlopidine or Triflusal or Abciximab or
Disintegrin or Echistatin or Eptifibatide or Lamifiban orOrbofiban or Roxifiban or Sibrafiban or Tirofiban or Xemilofiban or terutroban
or picotamide or prasugrel).tw,nm.
24. (Dispril or Albyl$ or Ticlid$ or Persantin$ or Plavix or ReoPro or Integrilin$ or Aggrastat).tw,nm.
25. or/6-24
26. Randomized Controlled Trials as Topic/
27. random allocation/
28. Controlled Clinical Trials as Topic/
29. control groups/
30. clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or
clinical trials, phase iv as topic/
31. double-blind method/
32. single-blind method/
33. Placebos/
34. placebo effect/
35. randomised controlled trial.pt.
36. controlled clinical trial.pt.
37. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv).pt.
38. (random$ or RCT or RCTs).tw.
39. (controlled adj5 (trial$ or stud$)).tw.
40. (clinical$ adj5 trial$).tw.
41. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
42. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
43. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
44. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
45. (placebo$ or sham).tw.
46. trial.ti.
47. (assign$ or allocat$).tw.
48. or/26-47
49. 5 and 25 and 48
50. exp animals/ not humans/
51. 49 not 50
Appendix 3. EMBASE (Ovid) search strategy
1. anticoagulant agent/ or antivitamin k/ or exp blood clotting inhibitor/ or exp
coumarin anticoagulant/ or defibrotide/ or dextran sulfate/ or fluindione/ or
glycosaminoglycan polysulfate/ or exp heparin derivative/ or lupus anticoagulant/ or
phenindione/
2. (anticoagul$ or antithromb$).tw.
3. (Vitamin K antagonist$ or VKA or VKAs).tw.
4. (direct$ adj5 thrombin adj5 inhib$).tw.
5. DTI$1.tw.
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6. ((factor Xa or factor 10a or fXa or autoprothrombin c or thrombokinase) adj5
inhib$).tw.
7. (activated adj5 (factor X or factor 10) adj5 inhib$).tw.
8. (acenocoumarol$ or dicoumarol$ or ethyl biscoumacetate$ or phenprocoumon$ or
warfarin$ or ancrod$ or citric acid$ or coumarin$ or chromonar$ or coumestro$ or
esculi$ or ochratoxin$ or umbelliferone$ or dermatan sulfate$ or dextran$ or edetic
acid$ or enoxaparin$ or gabexate$ or heparin$ or lmwh$ or nadroparin$ or pentosan
sulfuric polyester$ or phenindione$ or protein c or protein s or tedelparin$).tw.
9. (tinzaparin or parnaparin or dalteparin or reviparin or danaparoid or lomoparan or
org 10172 or mesoglycan or polysaccharide sulphate$ or sp54 or sp-54 or md805 or
md-805 or cy222 or cy-222 or cy216 or cy-216).tw.
10. (Marevan or Fragmin$ or Fraxiparin$ or Klexane).tw.
11. (argatroban or MD805 or MD-805 or dabigatran or ximelagatran or melagatran or
efegatran or flovagatran or inogatran or napsagatran or bivalirudin or lepirudin or
hirudin$ or desirudin or desulfatohirudin or hirugen or hirulog or AZD0837 or
bothrojaracin or odiparcil).tw.
12. (xabans or antistasin or apixaban or betrixaban or du 176b or eribaxaban or
fondaparinux or idraparinux or otamixaban or razaxaban or rivaroxaban or yagin or
ym 150 or ym150 or LY517717).tw.
13. or/1-12
14. exp antithrombocytic agent/
15. fibrinogen receptor/dt [Drug Therapy]
16. (antiplatelet$ or anti-platelet$ or antiaggreg$ or anti-aggreg$ or (platelet$ adj5
inhibit$) or (thrombocyt$ adj5 inhibit$)).tw.
17. (alprostadil$ or aspirin$ or acetylsalicylic acid or acetyl salicylic acid$ or
acetyl?salicylic acid or epoprostenol$ or ketanserin$ or ketorolac tromethamine$ or
milrinone$ or mopidamol$ or procainamide$ or thiophen$ or trapidil$ or picotamide$
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or ligustrazine$ or levamisol$ or suloctidil$ or ozagrel$ or oky046 or oky-046 or
defibrotide$ or cilostazol or satigrel or sarpolgrelate or kbt3022 or kbt-3022 or
isbogrel or cv4151 or cv-4151 or ((glycoprotein iib$ or gp iib$) adj5 (antagonist$ or
inhibitor$)) or GR144053 or GR-144053 or triflusal).tw.
18. (Argatroban or Beraprost or Cicaprost or Cilostazol or Clopidogrel or
Dipyridamole or Iloprost or Indobufen or Lepirudin or Pentosan Polysulfate or
Pentoxifylline or Piracetam or Prostacyclin or Sulfinpyrazone or Sulphinpyrazone or
Ticlopidine or Triflusal or Abciximab or Disintegrin or Echistatin or Eptifibatide or
Lamifiban or Orbofiban or Roxifiban or Sibrafiban or Tirofiban or Xemilofiban or
terutroban or picotamide or prasugrel).tw.
19. (Dispril or Albyl$ or Ticlid$ or Persantin$ or Plavix or ReoPro or Integrilin$ or
Aggrastat).tw.
20. or/14-19
21. 13 or 20
22. *basal ganglion hemorrhage/ or *brain hemorrhage/ or *brain ventricle
hemorrhage/ or *cerebellum hemorrhage/
23. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or
intraparenchymal or intraventricular or infratentorial or supratentorial or basal gangli$
or putaminal or putamen or posterior fossa or hemispher$ or stroke or apoplex$) adj5
(h?emorrhag$ or h?ematoma$ or bleed$)).ti.
24. 22 or 23 or (ICH or ICHs).ti.
25. randomized controlled trial/ or “randomized controlled trial (topic)”/
26. Randomization/
27. Controlled Study/
28. control group/
29. clinical trial/ or phase 1 clinical trial/ or phase 2 clinical trial/ or phase 3 clinical
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trial/ or phase 4 clinical trial/ or controlled clinical trial/
30. Double Blind Procedure/
31. Single Blind Procedure/ or triple blind procedure/
32. placebo/
33. drug comparison/ or drug dose comparison/
34. “types of study”/
35. random$.tw.
36. (controlled adj5 (trial$ or stud$)).tw.
37. (clinical$ adj5 trial$).tw.
38. ((control or treatment or experiment$ or intervention or surgical) adj5 (group$ or
subject$ or patient$)).tw.
39. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
40. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
41. placebo$.tw.
42. controls.tw.
43. or/25-42
44. meta analysis/ or “meta analysis (topic)”/ or “systematic review”/ or “systematic
review (topic)”/
45. meta analy$.tw.
46. metaanaly$.tw.
47. (systematic adj (review$1 or overview$1)).tw.
48. literature/
49. (cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or
cinhal or science citation index or bids or medline or pubmed).ab.
50. (reference list$ or bibliograph$ or hand-search$ or relevant journals or manual
search).ab.
51. (selection criteria or data extraction).ab.
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52. review.pt. or literature/ or review/
53. 51 and 52
54. 44 or 45 or 46 or 47 or 48 or 49 or 50 or 53
55. (letter or editorial).pt.
56. 54 not 55
57. 43 or 56
58. 21 and 24 and 57
59. limit 58 to human
Appendix 4. Trials register search strategies
1. US National Institutes of Health Ongoing Trials Register (ClinicalTrials.gov)
’Randomised’ AND ’intracerebral haemorrhage’
2. World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (apps.who.int/trialsearch)
’Intracerebral haemorrhage’ OR ’Intracerebral hemorrhage’ OR ’ICH’
3. ISRCTN Registry (www.isrctn.com)
’Intracerebral haemorrhage’ OR ’Intracerebral hemorrhage’ OR ’ICH’
4. Stroke Trials Registry - the Internet Stroke Center (www.strokecenter.org/trials/)
’Intracerebral haemorrhage’ OR ’Intracerebral hemorrhage’ OR ’ICH’
C O N T R I B U T I O N S O F A U T H O R S
All authors, Luke A Perry, EivindBerge, JoshuaBowditch, Elisabeth Forfang,OleMortenRønning,Graeme JHankey, ElmerVillanueva,
Rustam Al-Shahi Salman, contributed to planning, writing, and editing the review.
D E C L A R A T I O N S O F I N T E R E S T
Luke A Perry: none known
Eivind Berge: co-ordinating investigator of the ongoing STATICH trial.
Joshua Bowditch: none known
Elisabeth Forfang: managing investigator of the ongoing STATICH trial.
Ole Morten Rønning: none known
Graeme J Hankey: in the past three years, GJH has received honoraria from AC Immune for chairing the data safety monitoring
committee of two clinical trials of vaccines for Alzheimer’s disease, from Bayer for lecturing about stroke prevention in atrial fibrillation
at sponsored scientific symposia, and from Medscape, Web MD for participating in a discussion about stroke prevention in atrial
fibrillation for theheart.org.
Elmer Villanueva: none known
Rustam Al-Shahi Salman: Chief investigator of the UK REstart or STop Antithrombotics Randomised Trial (RESTART,
www.RESTARTtrial.org, ISRCTN71907627), which is funded by a special project grant from the British Heart Foundation.
42Antithrombotic treatment after stroke due to intracerebral haemorrhage (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• Medical Research Council, UK.
Senior clinical fellowship to RA-SS
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We separately grouped RCTs investigating short-term and long-term treatment, instead of performing subgroup analyses as our protocol
had specified.
We added two new outcomes: deep vein thrombosis and ICH growth, as we believe that they are of potential interest to consumers of
this review. The addition of the outcome deep vein thrombosis allowed us to include it as a secondary outcome in this review without
including it in another category (e.g. major ischaemic events). The addition of the ICH growth outcome is relevant to short-term
antithrombotic treatment and was considered after we decided to divide our analysis into two groups according to the duration of
antithrombotic drug use. The addition of these new outcomes did not result in any additional RCTs being included in this review.
We optimised the ’Summary of findings’ tables to better reflect the outcomes of interest related to short- and long-term treatment.
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